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Introduction
Fascaplysin (1), a pigment first reported in 1988 from the marine 
sponge Fascaplysinopsis [1], is the parent compound of a uniquely 
marine-derived structural class (Figure 1). Most members of this 
family possess a framework consisting of a planar, fused-pentacyclic 
alkaloid often as a quaternary salt. To date 27 analogs of fascaplysin (1) 
have been reported [2-9] and several studies have described a broad 
range of bioactivity properties for this class including antiangiogenesis 
[10], antibacterial [1], antimalarial [11] and cytotoxicity against 
various cancer cell lines [1-3,6,9]. A few specific targets for these 
biological activities have been defined, including DNA binding 
(possibly intercalation) [12] as well as inhibition of Cdk4 kinase [13], 
the latter leading to G1 phase arrest and apoptosis [14]. Our interest 
in the fascaplysin family is a consequence of their in vitro solid tumor 
selectivity, which we have noted for the parent compound 1 and analogs 
such as 3- and 10-bromo fascaplysin, compounds 3 and 4 respectively, 
as well as fascaplysin A (2) [2,3]. Our recent studies using fascaplysin 
A (2) demonstrated its in vivo therapeutic efficacy in a xenograft model 
[15]; thereby making this class of compounds ideal candidates for 
further preclinical development and eventual clinical trials. 
The natural history associated with the occurrence of fascaplysin 
(1) is somewhat unusual. It has been isolated from four different Indo-
Pacific sponge species, all belonging to the Thorectidae, including
Fascaplysinopsis reticulata, F. sp., Hyrtios cf. erecta, and a partially
classified Thorectandra. Analogs have also been isolated from two
distinct Didemnum tunicates [2]. The circumstance of this compound
being observed from multiple marine invertebrates in different marine
phyla is noteworthy and currently remains unexplained though parallel
biosynthetic machinery obviously exists in these biosynthetically
disparate taxa. Coincidentally, the isolated yields of fascaplysin analogs
reported from sponges and tunicates are high, suggesting that the
biosynthetic enzymes are robustly independent of invertebrate phyla
or taxonomic species [3]. The circumstance of having multiple natural
sources for a variety of fascaplysins greatly facilitates the next steps in
the pre-clinical evaluation of this class. Alternatively, these compounds
are also available from total synthesis [16-22], which if warranted could
be used to supply material for therapeutic evaluations. At this juncture,
the next step in the therapeutic evaluation of the fascaplysin class
consists of a rigorous pharmacokinetics assessment followed by careful
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Figure 1: Structures of the alkaloid salts, fascaplysin (1), and three 
analogs.
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Fascaplysin is a cytotoxic natural product isolated from a variety of Indo-Pacific marine organisms, primarily 
Fascaplysinopsis sponges and Didemnum tunicates. Positive xenograft studies involving this alkaloid structural 
class have indicated that fascaplysin may serve as an important lead compound for preclinical development. This 
study was undertaken as a prelude to a full pharmacokinetics and therapeutic assessment of fascaplysin. We 
describe here a simple plasma preparation and a rapid HPLC method for the detection of fascaplysin in mice. 
The method was validated by parameters including good linear correlation, a limit of quantification of 107.1 μg/
mL, and a good precision with a coefficient of variation of 0.92% for 10 μg/mL. This method provides excellent 
sensitivity and visualization of fascaplysin as a single peak allowing for rapid analysis of plasma samples involving 
absorption, distribution, and metabolism studies. A preliminary pharmacokinetics study in C57Bl/6 mice using 20.6 
mg/kg fascaplysin yielded a biphasic curve with T½α=16.7 min, T½β=11.7 h, and C0 of 17.1 μg/mL.
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in vivo bioactivity studies. We describe below a validated method to 
determine fascaplysin (1) concentration and stability in mouse plasma. 
The process consists of a simple extraction of plasma samples followed 
by isocratic HPLC analysis with UV detection of 1. 
Materials and Methods
Instruments 
A Waters Alliance HPLC system [including a Waters 2690 
Separations Module, a Waters 2996 Photodiode Array Detector, a 
Waters Symmetry Shield RP 18 reversed-phase column (3.9×150 mm, 
10 μm), and the Waters Empower software] (Milford, Massachusetts, 
USA), was used in this study for the determination of fascaplysin (1) in 
mouse plasma. A Beckman Coulter Allegra 21R Centrifuge (Fullerton, 
California, USA) was used to prepare the plasma and red blood cell 
samples for HPLC injection. 
Reagents
Fascaplysin (1) (HPLC peak purity >99%) was isolated as previously 
described [3]. All solvents were HPLC grade and obtained from Burdick 
& Jackson (Muskegon, Michigan, USA). 
Preparation of Plasma and Red Blood Cell (RBC) Samples
Mouse blood samples were collected by cardiac puncture using 
a 1mL syringe (with a 25-gauge needle) containing heparin as 
anticoagulant. Once the maximum amount of blood was collected, it 
was transferred to a 1.5 mL conical centrifuge tube and centrifuged 
at 14,000 rpm (equivalent to 19,000 g) at 4°C for 15 min to separate 
plasma and RBC. Plasma and RBC were separately transferred and 
stored in a freezer at -20°C. To prepare individual spiked standards, 
20 μL of fascaplysin stock solutions in water were added to 230 μL of 
plasma samples, 500 μL of methanol was added to each, inverted and 
vortexed for 1 min, and centrifuged at 19,000 g at 4°C for 30 min. The 
supernatant was added to 2.0 ml of water and the mixture was passed 
through a Sep-Pak® Vac 1 cc (100 mg) C8 cartridge. Fascaplysin (1) was 
eluted with 1.0 mL of methanol and evaporated to dryness using an 
Eppendorf Vacufuge® at 45°C. 100 μL of mobile phase buffer was added 
to each sample. The same procedure was used to prepare RBC samples 
for HPLC analysis. 
HPLC procedure 
Fascaplysin (1) in the eluted fraction was determined using a Waters 
SymmetryShield RP18 reversed-phase column (3.9×150 mm) with a 5 
μm particle size. The injection volume was 70 μL. The column oven was 
room temperature. The mobile phase was phosphoric acid/methanol/
water (1/20/79 v/v/v) at a flow rate of 1.0 mL/min. Detection was done 
at 302 nm. The results of the analysis are expressed in nanograms of 
fascaplysin (1) per mL of plasma.
Calibration curve
A stock solution of 20 μg/mL of fascaplysin (1) was prepared in 
water. The calibration curve was obtained with mouse plasma spiked 
with known amounts of the stock solution. The analyte was extracted 
according to the protocol described above. The calibration curve 
was obtained by plotting the peak area of fascaplysin (1) against its 
concentration in 7 spiked plasma standards (20, 10, 1, 0.5, 0.25, 0.1, and 
0.05 μg/ml) and performing a linear regression analysis. 
Pharmacokinetics study 
Fascaplysin (1) was administered i.v. to C57Bl/6 female mice at 20.6 
mg/kg in a volume of 0.25 mL saline, containing 5% DMSO and 5% 
Cremophor/Propylene glycol (60/40, v/v); two animals per time point 
were sacrificed at 5 min., 0.5, 1, 2, 4, and 24 hr after drug administration. 
Blood samples were collected and analyzed as described above. Animal 
treatment was in full accordance with the Institutional Animal Care 
and Use Committee (IACUC) Guidelines for the care and management 
of laboratory animals. 
Results and Discussion
The data gathered allows detection of fascaplysin (1) over a wide 
range of concentrations. The method developed here was validated 
according to the U.S. Pharmacopoeia [23] and the analytical 
performance parameters considered were selectivity, linearity, accuracy, 
precision, sensitivity, ruggedness, and peak symmetry [24].
Somewhat similar to a past study [25], seven parameters are used to 
validate the method and the analytical details are as follows:
Selectivity 
















Figure 2: Fascaplysin (1) UV spectrum showing key absorbance peaks 
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Figure 3: HPLC chromatogram of fascaplysin (1) (10 μg/mL) in mouse 
plasma (retention time at 19.2 min) with all other peaks assigned to the 
plasma as verified by comparison with the chromatogram of a control 
plasma.
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Ruggedness 
Ruggedness was shown by assaying 3 replicates of spiked plasma 
samples using 3 fascaplysin (1) concentrations on two consecutive days 
employing the corresponding linearity curve generated on the day 
the sample was assayed. As shown in (Table 3), intra- and inter-day 
assay results of a particular sample are essentially the same, indicating 
an acceptable ruggedness of the method for intra- and inter-day assay 
studies. In addition, three spiked samples (100, 250, and 500 ng/mL) 
were analyzed using slightly modified flow rates. As shown in (Table 
4), when the flow rate was reduced or increased to 0.9 or 1.1 mL/min, 
respectively, as compared to the normal 1mL/min. The assay results 
showed CV values of 2.1%, 2.0%, and 0.6%, further indicating that the 
present method is rugged with respect to minor changes of the flow 
rate.
Peak symmetry 
Tailing factor is defined as the distance from the front slope of the 
peak to the back slope (AB) divided by twice the distance from the demonstrated the potential wavelength for quantitative analysis: 263.4, 
302.6, and 408.8 nm. In all further studies, 302 nm was chosen. A 
typical chromatogram at 302 nm (Figure 3) for spiked plasma indicated 
that fascaplysin (1) was well-resolved and free from interference peaks. 
The use of a UV photodiode array detector allowed the confirmation of 
the identity of the chromatographic peak for fascaplysin (1) both by its 
retention time and UV spectrum. 
Linearity 
Calibration curves of fascaplysin (1) were prepared to determine the 
linearity of the method over the range of 50-20,000 ng/mL. Integrated 
peak areas were plotted against analyte concentration, and linear 
regression was performed by the least-squares method. The calibration 
curve generated using plasma as matrix showed a square of correlation 
coefficient of 0.998 (Figure 4). 
Accuracy 
The accuracy of the analytical method was determined by 
application of the method to analytes of known concentrations. 
Three spiked plasma samples (0.25, 10 and 20 μg/ml were prepared in 
triplicate and analyzed. The assay results were 0.253, 9.82, and 20.01 ng/
mL, indicating a recovery of 100.4%, 98.2%, and 101.2%, respectively 
for these samples. Therefore, the method is accurate (Table 1). 
Precision 
The precision of the analytical method was determined by analyzing 
a plasma sample spiked with 10 μg/ml of fascaplysin (1) injected ten 
times. Peak areas were considered for the determination. The precision, 
expressed as the percent coefficient of variation (CV), was 0.92% 
indicating that the method is precise (Table 2) [26]. 
Sensitivity 
Fascaplysin Std. Curve (Ave. n = 5)






















Figure 4: Fascaplysin (1) mouse plasma standard curve with a plot of 
concentration (μg/ml) vs. peak area (μV×sec). 






0.25 1023 0.253 100.4
10 50725 9.82 98.2
20 104033 20.01 101.2
Table 1: Average peak areas of three fascaplysin (1) standard concentrations and 
percent recoveries (n=3).


















Peak Area Average S.D. CV (%)
Day 1 Replicate 1 Replicate 2 Replicate 3
20 100171 108079 104033 104094 3954 3.80
10 49472 50855 51848 50725 1193 2.35
0.25 1052 997 1020 1023 27.6 2.70
Day 2
20 103266 99336 102708 101770 2126 2.08
10 50027 49735 50486 50083 379 0.76
0.25 1011 997 1022 1010 12.5 1.24
Table 3: Assay of a fascaplysin (1) standard sample over a period of 2 days.
Effect Flow Rate Variation on Assay (ng/mL)
Flow Rate (mL/min) Change Level 100 ng/mL 250 ng/mL 500 ng/mL
0.9 -0.1 101 243 501
1.0 0 98 249 505
1.1 +0.1 97 253 499
Avg ± SD 99 ± 2.08 258 ± 5.03 501 ± 3.06
CV (%) 2.1 2.0 0.6
Table 4: Assay results of three samples with known concentrations under different 
flow rates.
The limit of detection (LOD) and the limit of quantification (LOQ) 
were obtained by running six replicates of each standard for a full 
standard curve. A linear regression was performed on each standard 
curve and the standard deviation of the y-intercepts was computed. 
The LOD was computed by multiplying the standard deviation by 3.3, 
adding that number to the average y-intercept value and dividing by 
the average slope. Similarly, the LOQ was computed by multiplying the 
standard deviation by 10, adding that number to the average y-intercept 
value and dividing by the average slope (Table 5). The LOD for this 
method is 0.019 μg/ml and the LOQ is 0.107 μg/ml.
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center line of the peak to the front slope (2AC), with all measurements 
made at 5% of the maximum peak height [23] (Figure 5). The tailing 
factor computed for the fascaplysin peak (250 μg/mL) equals 1.08 
indicating that the peak symmetry is good.
A preliminary PK assessment was carried out in C57Bl/6 mice 
injected i.v. with 20.6 mg/kg (0.4 mg/mouse) of 1. The results are 
shown in (Figure 6), where the plasma level at 5 min was 14,533 ng/
mL, decreasing to 1809 ng/mL at 30 min, 351 ng/mL at 2 hr and then 
50 ng/mL at 24 hr. The T½α (17min) was calculated between 5 min and 
30 min; T½ β (11.7 hr) was calculated between 60 min and 1440 min); 
C0 was 17.1 μg/mL. Fascaplysin (1) levels in red blood cells (RBC) were 
also analyzed; 3.4 μg/mL at 5min decreasing to 127 ng/mL at 2 hr; after 
2 hr, the RBC concentration of fascaplysin (1) was not detectable. 
In summary, we have shown that each of the seven parameters 
discussed above provide a good basis for further biological evaluation 
of fascaplysin (1). The method described herein is suitable for analyzing 
plasma samples of fascaplysin (1). We have successfully developed a 
simple method to determine fascaplysin (1) in plasma, and present for 
the first time the absorption values of this compound in mouse blood 
from 5 min to 24 hr. Until now, no data have been published concerning 
absorption, bioavailability, and tissue distribution of fascaplysin (1). 
Future studies will evaluate both the pharmacokinetics and therapeutic 
efficacy of fascaplysin (1) in tumor-bearing mice.
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Table 5: Slopes and y-intercepts of five standard curves used to compute the LOD 
and LOQ.
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Figure 5: Fascaplysin (1) chromatogram from 250 µg/mL in plasma 
used for computing peak symmetry.
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Figure 6: Concentration vs. time curve of fascaplysin (1) in mouse 
plasma and red blood cells (RBC) at 5 min, 0.5, 1, 2, 4, and 24 hours.  
Volume 3 • Issue 6 • 1000150
J Anal Bioanal Techniques
ISSN:2155-9872 JABT, an open access journal 
Citation: Swartz KH, Valeriote FA, Media J, Johnson TA, Tenney K, et al. (2012) Development and Validation of a Simple Method for the Detection of 
Fascaplysin in Plasma. J Anal Bioanal Techniques 3:150. doi:10.4172/2155-9872.1000150
Page 5 of 5
fascaplysin, homofascaplysin C and analogues. Chem Commun (Camb) 46: 
4622-4624.
17. Zhidkov ME, Baranova OV, Kravchenko NS, Dubovistkii SV (2010) A new 
method for the synthesis of the marine alkaloid fascaplysin. Tetrahedron Lett 
51: 6498-6499. 
18. Garcia MD, Wilson AJ, Emmerson DP, Jenkins PR, Mahale S, et al. (2006) 
Synthesis, crystal structure and biological activity of beta-carboline based 
selective CDK4-cyclin D1 inhibitors. Org Biomol Chem 4: 4478-4484.
19. Radchenko OS, Novikov VL, Elyakov GB (1997) ChemInform Abstract: A 
Simple and Practical Approach to the Synthesis of the Marine Sponge Pigment 
Fascaplysin and Related Compounds. Cheminform 28: 5339-5342.
20. Molina P, Fresneda, PM, Garcia-zafra S, Almendros P (1994) ChemInform 
Abstract: Iminophosphorane-Mediated Syntheses of the Fascaplysin Alkaloid 
of Marine Origin and Nitramarine. Cheminform 26: 8851-8854.
21. Rocca P, Marsais F, Godard A, Quenguiener G (1994) ChemInform Abstract: 
A Short Synthesis of the Antimicrobial Marine Sponge Pigment Fascaplysin. 
Cheminform 25: 7917-7918.
22. Gribble GW, Pelcman B (1992) Total syntheses of the marine sponge pigments 
fascaplysin and homofascaplysin B and C. J Org Chem 57: 3636-3642. 
23. U.S. Pharmacopoeial Convention (2000) USP-NF.
24. Rambla-Alegre M, Esteve-Romero J, Carda-Broch S (2012) Is it really 
necessary to validate an analytical method or not? That is the question. J 
Chromatogr A 1232: 101-109.
25. Shaw J, Valeriote FA, Media J, Johnson TA, Amagata T, et al. (2010) 
Development and validation of a rapid method for the detection of latrunculol A 
in plasma. Anal Bioanal Chem 396: 1741-1744.
26. U.S. Department of Health and Human Services Food and Drug Administration 
(2000) Guidance for Industry, Analytical Procedures and Methods Validation, 
Chemistry, Manufacturing, and Controls Documentation. U.S. Department 
of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER), Center for Biologics Evaluation and 
Research (CBER).
